177839-89-3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 228422-44-4 (R)-1-benzyl-3-hydroxypropylamine 
• 115313-20-7 methyl 3-(R)-[N-(tert-butoxycarbonyl)amino]-4-phenylbutanoate 
• 36016-38-3 tert-Butyl N-hydroxycarbamate 
• 300-57-2 allylbenzene 
• 55177-35-0 (E)-4-phenyl-2-butenal 
• 101555-61-7 (R)-3-t-butoxycarbonylamino-4-phenylbutyric acid 
• 18942-49-9 Boc-D-Phe-OH 

Downstream Products

• 101555-61-7 (R)-3-t-butoxycarbonylamino-4-phenylbutyric acid 
• 219862-76-7 (R)-[3-Bromo-1-(phenylmethyl)propyl]carbamic acid 1,1-dimethylethyl ester 
• 372186-56-6 (3R,6S)-3-(3-Azido-propyl)-6-benzyl-piperidin-2-one 
• 372186-57-7 (3S,6S)-3-(3-Azido-propyl)-6-benzyl-piperidin-2-one 
• 372186-53-3 2-(3-tert-butoxycarbonylamino-4-phenyl-butyl)-malonic acid dimethyl ester 
• 372186-58-8 (3R,6S)-3-(3-Azido-propyl)-6-benzyl-2-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 372186-59-9 (3S,6S)-3-(3-Azido-propyl)-6-benzyl-2-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 372186-55-5 2-(3-azido-propyl)-5-tert-butoxycarbonylamino-6-phenyl-hexanoic acid 
• 372186-54-4 2-(3-azido-propyl)-2-(3-tert-butoxycarbonylamino-4-phenyl-butyl)-malonic acid dimethyl ester 

Relevant academic research and scientific papers

Practical asymmetric synthesis of Sitagliptin phosphate monohydrate

Optically pure sitagliptin phosphate monohydrate is efficiently and practically synthesized through a chiral hemiacetal as the key intermediate in 54% overall yield starting from (E)-4-(2,4,5-trifluorophenyl)but-2-enal and N-boc-protected hydroxylamine. The chiral hemiacetal fragment is constructed by a tandem aza-Michael/hemiacetal reaction catalyzed by an organocatalyst and the influence of acidity of Br?nsted acid on tandem aza-Michael/hemiacetal reaction is researched in detail.

Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Provided herein are Heterocyclic Compounds having the following structure: wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

Inhibitors of farnesyl protein transferase

Disclosed are quinoline and benzazepine derivatives that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.

Preparation of 'carba' dipeptides bearing a basic side-chain at the C-terminus: Synthesis of enantiopure Boc-D-Phe-Ψ[CH2CH2]-L-Arg(NO2)-OH and Boc-D-Phe-Ψ[CH2CH2]-D-Arg(NO2)OH

A new approach to synthesize 'carba' Ψ[CH2CH2] dipeptides, e.g. Boc-D-Phe-Ψ[CH2CH2]-L-Arg(NO2)-OH and Boc-D-Phe-Ψ[CH2CH2]-D-Arg(NO2)-OH, is described.

A novel approach to homochiral β-amino acids 1

An efficient synthesis of γ-aryl or alkyl substituted β-amino acids starting from N-Cbz-L-homoserine lactone via the formation of α-amino aryl, alkenyl or alkynyl ketones with the original α-carbon chirality retained as such is described. Copyright